Table: Towa Pharmaceutical - 6-MTH group results
Nov 12 (Reuters)-
Towa Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2021 Sep 30, 2020 Mar 31, 2022
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 82.25 74.64 166.70
(+10.2 pct) (+34.9 pct) (+7.6 pct)
Operating 10.31 8.91 19.30
(+15.7 pct) (-3.3 pct) (-3.1 pct)
Recurring 13.01 8.86 22.11
(+46.9 pct) (-9.1 pct) (+18.4 pct)
Net 9.24 6.38 15.44
(+44.8 pct) (-9.7 pct) (+10.6 pct)
EPS 187.79 yen 129.68 yen 313.73 yen
EPS Diluted 183.63 yen 126.57 yen
Ann Div 44.00 yen 51.00 yen
-Q2 div 27.00 yen 22.00 yen
-Q4 div 22.00 yen 24.00 yen
NOTE - Towa Pharmaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4553.T
Recent news on TOWA PHARMACEUTICAL
See all newsTable: Towa Pharmaceutical -Q1 group results
Notice Of Acquisition Of Shares Of Tanabe Pharma Factory And Transfer Of Manufacturing And Marketing Approvals
Brief: Breckenridge Launches Tofacitinib Tablets, Generic Equivalent Of Xeljanz By Pfizer
Table: Towa Pharmaceutical -2025/26 parent results
Table: Towa Pharmaceutical -2025/26 group results